Annals of Clinical Microbiology | 卷:25 |
Analysis of Neutralization Antibodies in Patients With Mild COVID-19 Infection After 100 Days Using Microneutralization Test | |
Kyu-Sun Lee1  Byung-Han Ryu2  Sunjoo Kim3  Seungjun Lee3  Hye Ryun Yang4  Min-Ju Ahn5  Dae Gwin Jeong5  | |
[1] Bionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon,; | |
[2] Department of Infectious Diseases, Gyeongsang National University Changwon Hospital, Changwon,; | |
[3] Department of Laboratory Medicine, Gyeongsang National University Changwon Hospital, Changwon,; | |
[4] Gyeongnam Center for Infectious Disease Control and Prevention, Changwon; | |
[5] Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon,; | |
关键词: antibody; covid-19; neutralization; sars-cov-2; | |
DOI : 10.5145/ACM.2022.25.1.4 | |
来源: DOAJ |
【 摘 要 】
Neutralizing antibodies play a critical role in blocking viral infections and in viral clearance during acute infection. The microneutralization assay and enzyme-linked immunosorbent assay (ELISA) targeting the receptor binding domain were performed for 30 patients with mild coronavirus disease (COVID)-19 infections. The elapsed number of days between sample collection and diagnosis was 115 days, and real-time polymerase chain reaction (PCR) cycle threshold (Ct) values at diagnosis were recorded. Clinical characteristics and Ct values were compared between neutralization antibody-positive and -negative patients as measured by the microneutralization assay. Neutralization antibody-positive patients (n = 9) were likely to be older, have low Ct values, have more pneumonia during admission, and have a higher optical density in ELISA than the neutralization antibody-negative patients (n = 21). Elderly people seemed to have a higher viral load causing more pneumonia and to produce more neutralization antibodies. Neutralization antibodies persisted in only 30% of patients as detected by microneutralization test after 100 days of diagnosis.
【 授权许可】
Unknown